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ABSTRACT
Objective: To investigate the regulatory effect of
tumour necrosis factor (TNF) blockade with infliximab
on the distribution of peripheral blood monocyte
subpopulations in patients with rheumatoid arthritis
(RA) and ankylosing spondylitis (AS).
Methods: Purified CD11b+CD14+ monocytes from 5
patients with RA and 5 AS were analysed ex vivo
before and after infliximab treatment by flow cytometry
for CD16, CD163, CD11b, C-C chemokine receptor
type 2 (CCR2) and CXC chemokine receptor 4 (CXCR4)
at baseline and at days 2, 14, 84 and 168 after the first
infliximab administration. Serum levels of the stromal
cell-derived factor (SDF)-1 and monocyte chemotactic
peptide (MCP)-1 at different time points were
measured in either patient group before and on
infliximab treatment.
Results: Anti-TNF treatment with infliximab led to a
significant increase of circulating CD11b+ non-classical
and a concomitantly decrease of CD11b+ classical
monocytes, to a decline in SDF-1 levels and reduced
expression of CCR2 and CXCR4 on non-classical
monocyte subpopulation.
Conclusions: Our study shows, that TNFα blockade
by infliximab resulted in a dichotomy of the regulation
of classical and non-classical monocytes that might
have substantial impact on inhibition of
osteoclastogenesis and of subsequent juxta-articular
bone destruction and systemic bone loss in RA
and AS.
INTRODUCTION
Tumour necrosis factor (TNF) inhibition
leads to a reduction of soluble cell adhesion
molecules, chemokines and their receptors in
patients with rheumatoid arthritis (RA)1 2 or
ankylosing spondylitis (AS).3 In Crohn’s
disease, inﬂiximab therapy has been found to
increase the frequency of circulating CD14
+CD16+ monocytes.4 These non-classical
monocytes have been found to produce large
amounts of TNF5 but are not able to differen-
tiate into osteoclasts,6 whereas classical mono-
cytes (CD14+CD16−) are mainly producers
of interleukin-106 and are able to differenti-
ate into osteoclasts.6 Differential therapeutic
regulation of these monocyte subsets may
explain the bone-sparing effect of TNF inhibi-
tors. This has yet not been elucidated ex vivo.
METHODS
Patients with RA according to the ACR 1987
revised criteria7 and patients with AS accord-
ing to the New York criteria8 were included
in the present study. Patients who fulﬁlled
the EULAR9 and ASAS10 response criteria to
treatment with inﬂiximab after 3 months
were analysed based on data sets obtained at
Key questions
What is already known about this subject?
▸ Tumour necrosis factor (TNF) inhibition leads to
a reduced bone resorbing activity of osteoclast
precursor cells in patients with rheumatoid arth-
ritis (RA) or ankylosing spondylitis (AS).
What does this study add?
▸ We demonstrated that anti-TNFα treatment
response on infliximab in patients with RA and
AS is associated with a rapid decline in the
number of circulating classical monocytes,
reduced expression of CXC chemokine receptor
4, C-C chemokine receptor type 2 and circulat-
ing stromal cell-derived factor-1.
How might this impact on clinical practice?
▸ Provide a mechanistic understanding of the anti-
osteoclastogenic and bone preserving effect of
anti-TNFα treatment on infliximab in patients
with RA and AS.
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all deﬁned time points during the entire study period.
Concomitant medications such as corticosteroids
>7.5 mg prednisone equivalent daily, bisphosphonates,
antiepileptics, heparin, oestrogens, testosterone, thiazids
and ACE inhibitors were exclusion criteria. Repetitive
blood samples from patients were obtained by venipunc-
ture. To elucidate changes of monocyte subsets, posi-
tively selected (CD14 microbeads; Miltenyi Biotec,
Bergisch-Gladbach, Germany) CD14+ peripheral blood
monocytes were measured for CD14, CD16, CD163,
CD11b, C-C chemokine receptor type 2 (CCR2) and
CXC chemokine receptor 4 (CXCR4; antibodies all
from BD Pharmingen, San Diego, California, USA)
expression by FACS at baseline and days 2, 14, 84 and
168 after the ﬁrst inﬂiximab administration.11 Inﬂiximab
was administered intravenously at baseline and after 2, 4,
6, 12 and 24 weeks (3 mg/kg in patients with RA and
5 mg/kg in patients with AS)11 and adjusted according
to clinical response thereafter. Blood was examined for
changes in monocytes subsets, circulating levels of
stromal cell-derived factor (SDF)-1 (Quantikine Kit
(R&D Systems, Minneapolis, Minnesota, USA) and of
monocyte chemotactic peptide (MCP)-1 (BD
Pharmingen) which were determined by ELISA. The
minimum detectable dose of SDF-1 was 18 pg/mL and
of MCP-1 19 pg/mL.
Because of only 10 patients tested we used repeated
measures analysis of variance and post hoc Bonferroni’s
Multiple Comparison Test (95% CIs), signiﬁcant results
(p<0.05) are depicted with an asterisk. Exact p values
were calculated by one-tailed paired t test. Analysis and
graphs were performed using prism 5 (GraphPad V.5.0).
RESULTS
Patient’s characteristics prior to infliximab treatment
Baseline characteristics of the 10 patients included in
the present study are shown in table 1. Based on the
strict exclusion criteria for co-medication and for deﬁn-
ition of active disease and of treatment response, the
number of ﬁnally included patients was only 10. As
anticipated, the majority of RA patients were postmeno-
pausal middle-aged females, whereas the AS group
included only younger and middle-aged males. Therapy
with symptomatic and/or disease-modifying antirheu-
matic drugs remained unchanged during the study
period. Two patients with AS had no co-medication at
study entry and during the entire study period. Before
the ﬁrst inﬂiximab infusion, all patients had active
disease according to the Disease Activity Score 28
(DAS28)9 and Bath Ankylosing Spondylitis Disease
Activity Index (BASDAI).12
Increase of non-classical and decrease of classical
monocytes during infliximab treatment
Throughout the study period, the number of CD11b
+CD14+ monocytes remained constant in either patient
population (range 84.8–98.6%). However, the monocyte
subpopulations of interest exhibited a contrasting
regulation pattern on inﬂiximab treatment both in
patients with RA and AS (ﬁgure 1). Whereas the non-
classical (CD11b+CD14+CD163−CD16+) subpopulation
increased over time (for RA: range of 7.1% up to 25.5.%;
range of p value compared with baseline from 0.09 to
0.013; for AS: range of 3.4% up to 40.3%; range of p value
compared with baseline from 0.34 to 0.045), the classical
(CD11b+CD14+CD163+CD16−) subpopulation decreased
(for RA: range of 40.1% down to 0.2%, range of p value
compared with baseline from 0.14 to 0.003; for AS: range
47% down to 1.1%, range of p value from 0.023 to 0.002).
Downregulation of circulating ligand levels
(SDF-1 and MCP-1) and expression of their
receptors (CCR2 and CXCR4) on infliximab treatment
Serum levels of the corresponding cytokines (SDF-1 and
MCP-1) at different time points were measured concomi-
tantly in either patient group before and on inﬂiximab
treatment. We found a reduction of circulating SDF-1
levels over time in patients with RA and AS and less sig-
niﬁcant also of MCP-1 levels after 6 months in patients
with RA only (ﬁgure 2A). In addition, we observed a sig-
niﬁcant and rapid downregulation of the percentage of
CXCR4+ and CCR2+ classical monocytes 2 days, 2 weeks,
3 months and 6 months after initiation of inﬂiximab
treatment compared with baseline values in patients with
RA (p values of 0.026, 0.037, 0.028 and 0.02; p values of
0.046, 0.029, 0.029 and 0.029, respectively; ﬁgure 2B).
DISCUSSION
In the present study, we demonstrated that in patients
with RA and AS anti-TNFα treatment response on
Table 1 Patient’s baseline characteristics
RA (n=5) AS (n=5)
Female (n) 4 0
Male (n) 1 5
Age, years (range) 48.6 (39–59) 37.2 (28–47)
Disease duration, years
(range)
5.2 (1.5–11) 5.48 (3–10)
DAS28,9 mean (range) 4.93 (3.54–
5.94)
–
BASDAI,12 mean (range) – 4.27 (3.83–
4.6)
ESR, mm/h, mean (range) 21 (10–41) 38 (12–71)
CRP, mg/L, mean (range) 6 (3–17) 27 (3–49)
RF+ (%) 80 0
aCCP+ (%) 80 0
HLA-B27+ (%) 0 100
Prednisone 7.5 mg/d (n) 3 0
Methotrexate 15 mg/w (n) 2 0
Leflunomide 20 mg/d (n) 2 0
NSAIDs (n) 3 3
AS, ankylosing spondylitis; BASDAI, Bath Ankylosing Spondylitis
Disease Activity Index; CRP, C reactive protein; DAS28, Disease
Activity Score 28; RA, rheumatoid arthritis.
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inﬂiximab is associated with a rapid decline in the
number of circulating classical (CD11b+CD14+CD163
+CD16−) monocytes with reduced expression of
CXCR4, CCR2 and decreased levels of circulating SDF-1.
In contrast, we observed a constant accumulation of cir-
culating non-classical (CD11b+CD14+CD163−CD16+)
monocytes. Only in patients with RA we found also a
decline of circulating MCP-1. Thus, our study shows, that
successful TNFα blockade by inﬂiximab resulted in a
dichotomy in the regulation of monocytes subpopula-
tions that may have n substantial impact on reduced
bone resorbing activity of osteoclast precursor cells
(OPCs) that we have observed in a previous study.11
In order to get a deeper insight into the nature of
potential inhibitory mechanisms, we focused on factors
inﬂuencing the recruitment and migration behaviour of
these cells. We ﬁrst demonstrated that besides reducing
the pool of circulating classical CD163+CD16− mono-
cytes, inﬂiximab treatment did also reduce the amount
of CD163+CD16− cells bearing the chemokine receptors
CXCR4 and CCR2 and concomitantly reduced the levels
of corresponding circulating chemokines. These ﬁnd-
ings may suggest that besides promotion of apoptosis of
monocytes as described previously13 a speciﬁc inhibition
of recruitment and/or trafﬁcking of classical monocytes
and of subsequent osteoclasts development at inﬂamma-
tory sites might contribute to the inhibition of bone
resorption by inﬂiximab in TNFα-mediated chronic
inﬂammatory processes. Regarding the inhibition of
recruitment of OPCs from bone marrow corresponding
mechanisms have been already described previously in
patients with psoriatic arthritis.14 The inhibition of
SDF-1 secretion, that is, from activated synovial ﬁbro-
blasts and reduced CXCR4 expression on circulating
classical monocytes15 might ﬁnally inhibit recruitment,
directed trafﬁcking into inﬂamed peripheral tissues and
subsequent osteoclastogenesis.
The peripheral pooling of CD16+ monocytes and of
Th1 cells16 on inﬂiximab treatment might reﬂect an anti-
inﬂammatory effect which is hypothetically mediated by
the downregulation of expression of adhesion molecules
on endothelial cells and by subsequent inhibition of
transmigration of inﬂammatory cells through postcapil-
lary venules into inﬂammatory sites.17 18 Our ﬁnding of a
reduced recruitment of CD163+ monocytes during inﬂix-
imab treatment is also in good accordance with previous
results demonstrating a reduced inﬂux of CD163+ mono-
cytes into the synovial compartment of patients with RA
and spondyloarthritis,19 a reduced osteoclastogenesis in
the synovial compartment of patients with psoriatic arth-
ritis15 and with the reversal of the increased frequency of
CD11bhigh+ osteoclast precursors and enhanced osteo-
clastogenesis in TNF-tg mice on anti-TNFα treatment in
vivo.20
Figure 1 Changes in non-classical (CD11b+CD14+CD163−CD16+) and classical (CD11b+CD14+CD163+CD16−) monocytes
over time in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Data are shown as percentage of CD11b
+CD14+ cells and median (*p<0.05).
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A limitation of our study is the low numbers of
included patients that could be analysed
longitudinally.
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Figure 2 (A) Reduction of
circulating stromal cell-derived
factor (SDF)-1 levels over time in
patients with rheumatoid arthritis
(RA) and ankylosing spondylitis
(AS) and less significant also of
monocyte chemotactic peptide
(MCP)-1 levels after 6 months in
patients with RA only. Data are
shown as absolute values and
median (*p<0.05).
(B) Downregulation of the
percentage of CXCR4+ and
CCR2+ classical monocytes
2 days, 2 weeks, 3 months and
6 months after initiation of
infliximab treatment compared
with baseline values in patients
with RA. Data are shown as
percentage of CD11b+CD14
+CD163+CD16− cells and
median (*p<0.05).
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